The antipsychotic measure went hybrid
The long-stay antipsychotic measure stopped being an MDS question this year. Not every building has caught up to what that means.
CMS re-specified it as a hybrid. It now pulls pharmacy claims, physician and outpatient claims, Medicare Advantage encounter data, and enrollment files alongside the MDS. The reasons were specific: the old version missed use falling outside the 7-day look-back, and schizophrenia was reported on the MDS more often than claims supported.
Two things about the new version surprise people.
A resident triggers on a pharmacy fill during the quarter while she's in your building, even if the medication was never given, or was stopped days later. And stopping it later doesn't untrigger her. Your improvement lands on Care Compare in some future quarter, not the one you fixed it in.
That changes where you can actually act. The measure now watches the whole quarter, so it follows care transitions, and transitions are where antipsychotics tend to get started. A resident comes back from a hospital stay or an emergency visit, and an order that made sense on a hard night in an unfamiliar room comes back with her.
Your MDS team can code this flawlessly and still watch the number climb. The work moved upstream of them, to whoever reviews what she returned on that first week, and asks whether the agitation has a physical cause worth ruling out first.
When a resident comes back on a new antipsychotic, who reviews it, and how soon?
Source: AAPACN, "Quality Measure IQ Series: The Re-Specified Long-Stay Antipsychotic Measure" (Feb 3, 2026)
Follow for the next one: Dr. Raj Desai · Precision Pain & Rehabilitation Management on LinkedIn.